Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study

J Crohns Colitis. 2019 Apr 26;13(5):539-540. doi: 10.1093/ecco-jcc/jjy202.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Drug Monitoring*
  • Gastrointestinal Agents
  • Humans
  • Inflammatory Bowel Diseases*
  • Infliximab

Substances

  • Gastrointestinal Agents
  • Infliximab